The FDA banned the use of two monoclonal antibody treatments. The Biden Admin would ban the distribution of monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly because of the ineffectiveness against Omicron.
“We want to make sure that patients get treatments that are effective, not treatments that don’t work,” said one of the officials, who spoke on the condition of anonymity to describe internal discussions. The Washington Post reported.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
‘’The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies. The agency will not revoke the authorizations in case the treatments become useful against a future coronavirus variant.’’ The report continued.
Biden’s Admin officials emphasized that several therapies are effective against Omicron as sotrovimab and the antiviral pills by Pfizer.
The use of ramdesivir is an outpatient therapy that got the green light from the regulators.
Watch the video below: